MR-guided stereotactic thermal ablation was developed as a minimally i
nvasive brain tumour treatment. Eighteen primary or metastatic brain t
umours were treated in 15 patients. The entire procedure was performed
under local anaesthesia in an MR suite, The outcome was analysed with
13-30 months of clinical follow-up, Local control was achieved in nin
e tumours in eight patients. Among them four patients with five tumour
s were disease-free for more than 22 months after the treatment. four
patients died from systemic disease or primary cancer while metastatic
brain tumours were locally controlled. Local recurrence was seen in h
ypervascular metastatic tumours and a glioblastoma multiforme. For met
astatic and primary brain tumours, MR provides not only accurate local
ization of brain tumour but also near real time thermal monitoring of
acute tissue changes, This immediate imaging feedback facilitates safe
and complete coagulation of the brain tumour. Based on our limited sa
mple experiences, it is hoped that relatively long-term local control
can be obtained in non-hypervascular metastases. MR-guided stereotacti
c RF thermal ablation is an attractive and promising technique, offeri
ng a potential treatment alternative for patients with previously trea
ted brain tumour or systemic illness preventing other more conventiona
l therapies.